ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants
Can provide protection for millions of immuno-compromised and elderly who are most vulnerable to COVID-19
Ghent, Belgium, 15 January 2024: ExeVir Bio, a biotech company developing robust heavy chain-only antibody therapies for broad protection against infectious diseases, today announced new data demonstrating that its antibodies are highly potent in neutralizing currently circulating COVID-19 Omicron variants.
